Tulip joins Neoprobe as exec VP, business chief

Thomas Tulip, PhD, has joined radiopharmaceutical developer Neoprobe as executive vice president and chief business officer.

Prior to joining Neoprobe, Tulip held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging, Bristol Myers Squibb (BMS) and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management.

Most recently, as president of Alseres Molecular Imaging, Tulip led efforts to develop markets for a Phase III neuroimaging agent. While at DuPont and BMS, he helped develop, commercialize and manage the nuclear cardiology franchise.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.